S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:ARNA

Arena Pharmaceuticals Competitors

$67.05
+1.74 (+2.66 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$65.00
Now: $67.05
$67.39
50-Day Range
$63.85
MA: $74.91
$87.71
52-Week Range
$32.95
Now: $67.05
$90.19
Volume366,607 shs
Average Volume678,852 shs
Market Capitalization$3.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.86

Competitors

Arena Pharmaceuticals (NASDAQ:ARNA) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying ARNA stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Arena Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Amgen and Arena Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Arena Pharmaceuticals001403.00

Amgen presently has a consensus target price of $254.08, indicating a potential upside of 10.85%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Amgen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Insider & Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Amgen and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.71$7.84 billion$14.8215.47
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Amgen has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Arena Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Insider & Institutional Ownership

75.2% of Gilead Sciences shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Gilead Sciences and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.44$5.39 billion$6.1410.03
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Gilead Sciences has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Gilead Sciences and Arena Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Arena Pharmaceuticals001403.00

Gilead Sciences presently has a consensus target price of $76.1538, indicating a potential upside of 23.71%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Gilead Sciences.

Profitability

This table compares Gilead Sciences and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Summary

Arena Pharmaceuticals beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.26$1.18 billion$4.2953.22
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Vertex Pharmaceuticals has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Arena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072312.81
Arena Pharmaceuticals001403.00

Vertex Pharmaceuticals presently has a consensus target price of $290.8276, indicating a potential upside of 27.38%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Summary

Vertex Pharmaceuticals beats Arena Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.68$2.12 billion$21.4722.94
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Regeneron Pharmaceuticals has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Regeneron Pharmaceuticals and Arena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0101312.63
Arena Pharmaceuticals001403.00

Regeneron Pharmaceuticals presently has a consensus target price of $628.52, indicating a potential upside of 27.63%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Regeneron Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Summary

Regeneron Pharmaceuticals beats Arena Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

78.9% of Biogen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Biogen and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.63$5.89 billion$33.577.32
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Biogen has higher revenue and earnings than Arena Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Biogen and Arena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151302.24
Arena Pharmaceuticals001403.00

Biogen presently has a consensus target price of $306.1290, indicating a potential upside of 24.51%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Biogen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Seagen (NASDAQ:SGEN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Seagen and Arena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Arena Pharmaceuticals001403.00

Seagen presently has a consensus target price of $176.75, indicating a potential downside of 1.38%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Seagen.

Insider and Institutional Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Seagen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
Arena Pharmaceuticals-5,727.22%-33.17%-30.41%

Valuation and Earnings

This table compares Seagen and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million35.25$-158,650,000.00($1.33)-134.76
Arena Pharmaceuticals$806.43 million4.84$397.55 million$7.698.72

Arena Pharmaceuticals has lower revenue, but higher earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Arena Pharmaceuticals on 9 of the 15 factors compared between the two stocks.


Arena Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$229.21+1.0%$133.44 billion$23.36 billion18.48
Gilead Sciences logo
GILD
Gilead Sciences
2.7$61.56+1.1%$77.17 billion$22.45 billion63.46
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$228.32+0.6%$59.37 billion$4.16 billion28.83Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.3$492.45+1.3%$52.55 billion$7.86 billion19.07
Biogen logo
BIIB
Biogen
2.0$245.87+0.7%$37.83 billion$14.38 billion8.14Analyst Report
Insider Buying
Analyst Revision
Seagen logo
SGEN
Seagen
1.4$179.23+0.5%$32.32 billion$916.71 million-118.70Analyst Downgrade
Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.1$120.51+0.5%$26.37 billion$4.99 billion28.16Insider Selling
Exact Sciences logo
EXAS
Exact Sciences
1.6$132.87+1.7%$19.99 billion$876.29 million-60.12Insider Selling
Heavy News Reporting
Incyte logo
INCY
Incyte
1.5$83.14+0.3%$18.21 billion$2.16 billion-52.96
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.56+1.2%$15.05 billion$219.75 million-16.55
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.61+0.6%$14.45 billion$1.70 billion18.22
Repligen logo
RGEN
Repligen
1.4$188.33+0.6%$9.91 billion$270.24 million324.71Increase in Short Interest
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.53+2.3%$9.02 billion$788.10 million103.80Insider Selling
Novavax logo
NVAX
Novavax
1.8$126.25+2.3%$8.04 billion$18.66 million-45.91Analyst Downgrade
Increase in Short Interest
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$51.22+0.5%$7.16 billion$1.12 billion106.71Analyst Upgrade
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.18+5.6%$6.04 billion$182.24 million-20.16Insider Selling
Heavy News Reporting
United Therapeutics logo
UTHR
United Therapeutics
1.6$133.47+2.6%$5.93 billion$1.45 billion13.70Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Exelixis logo
EXEL
Exelixis
1.9$18.98+0.7%$5.89 billion$967.78 million39.54
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.12+2.2%$5.42 billion$195.99 million250.75Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.79+0.4%$4.39 billion$1.11 billion26.62
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.47+2.5%$3.98 billion$36.13 million-85.78Analyst Downgrade
OPKO Health logo
OPK
OPKO Health
1.9$4.76+2.9%$3.19 billion$901.90 million-14.42Analyst Downgrade
Heavy News Reporting
Alkermes logo
ALKS
Alkermes
1.1$19.08+0.4%$3.04 billion$1.17 billion-41.48Analyst Upgrade
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.98+3.3%$1.92 billion$428.41 million17.36Unusual Options Activity
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$118.47+0.1%$1.83 billionN/A-10.70
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$18.88+1.1%$1.42 billion$638.60 million-7.26
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.99+1.3%$1.41 billion$102.43 million-12.04Analyst Upgrade
Heavy News Reporting
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$86.56+1.4%$1.39 billion$120.28 million-87.43Analyst Downgrade
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$35.40+0.6%$1.17 billion$252 million-3.62
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.02+3.3%$1.13 billion$82.27 million-14.68Increase in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$6.10+15.7%$1.08 billion$48.83 million-8.03Unusual Options Activity
Heavy News Reporting
Innoviva logo
INVA
Innoviva
1.1$10.51+0.9%$1.07 billion$261.02 million5.36Analyst Upgrade
Codexis logo
CDXS
Codexis
1.1$17.56+3.0%$1.04 billion$68.46 million-50.17Unusual Options Activity
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$19.61+1.0%$775.91 million$3.57 million-8.79
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$13.35+2.0%$730.14 million$227.19 million6.39Analyst Report
Analyst Revision
Heavy News Reporting
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.87+1.8%$710.64 million$109.33 million-3.99
MannKind logo
MNKD
MannKind
0.9$2.95+3.4%$686.17 million$63.04 million-14.05Decrease in Short Interest
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.53+0.0%$649.81 million$38.19 million37.51Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$3.33+1.8%$633.20 million$150.05 million-3.06
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.83+2.8%$606.44 million$150,000.00-4.04
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$5.16+0.2%$568.49 million$35.22 million-3.77
Geron logo
GERN
Geron
1.4$1.81+1.7%$561.95 million$460,000.00-5.17
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.08+2.3%$520.46 million$59.29 million-22.00
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.30+2.1%$468.09 million$143.01 million-1.01
Molecular Templates logo
MTEM
Molecular Templates
1.7$8.95+1.5%$447.18 million$22.27 million-4.39
Verastem logo
VSTM
Verastem
1.5$2.19+3.7%$371.81 million$17.46 million-1.55
XOMA logo
XOMA
XOMA
1.3$32.99+1.5%$363.62 million$18.37 million-29.72Analyst Downgrade
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.58+1.6%$294.71 million$54.76 million-1.94Analyst Upgrade
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.78+1.8%$260.49 million$36.63 million-3.27Heavy News Reporting
This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.